Sabio lab

at the CNIC

Tag: lipid metabolism (page 1 of 2)

¿Quién dirige la orquesta en la obesidad? (15 March 2018)

On Thursday 15 March 2018, at the XIV Congress of the Spanish Society for the Study of the Obesity (SEEDO) Guadalupe Sabio (Centro Nacional de Investigaciones Cardiovasculares Carlos III) and Amaia Rodríguez Murueta-Goyena (Clínica Universidad de Navarra) will debate about which is the main organ orchestrating the diseases caused by obesity.

SEEDO 2018

Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis

Begoña Porteiro, Marcos F. Fondevila, Xabier Buque, Maria J. Gonzalez-Rellan, Uxia Fernandez, Alfonso Mora, Daniel Beiroa, Ana, Senra, Rosalia Gallego, Johan Fernø, Miguel López, Guadalupe Sabio, Carlos Dieguez, Patricia Aspichueta & Rubén Nogueiras.

Recent reports have implicated the p53 tumor suppressor in the regulation of lipid metabolism. We hypothesized that the pharmacological activation of p53 with low-dose doxorubicin, which is widely used to treat several types of cancer, may have beneficial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

Hematoxylin&eosin and oil red O staining of liver sections.

We used long-term pharmacological activation of p53 by i.p. or oral administration of low-dose doxorubicin in different animal models of NAFLD (high fat diet containing 45% and 60% kcal fat) and NASH (methionine- and choline-deficient diet and choline deficiency combined with high fat diet). We also administered doxorubicin in mice lacking p53 in the liver and in two human hepatic cells lines (HepG2 and THLE2).

The attenuation of liver damage was accompanied by the stimulation of fatty acid oxidation and decrease of lipogenesis, inflammation, and ER stress. The effects of doxorubicin were abrogated in mice with liver-specific ablation of p53. Finally, the effects of doxorubicin on lipid metabolism found in animal models were also present in two human hepatic cells lines, in which the drug stimulated fatty acid oxidation and inhibited de novo lipogenesis at doses that did not cause changes in apoptosis or cell viability.

These data provide new evidence for targeting p53 as a strategy to treat liver disease


PhD positions with “La Caixa” – INPhINIT fellowship programme

Our laboratory is offering two research projects for talented and highly motivated Early-Stage Researchers within the INPhINIT ”la Caixa” Fellowship Programme:

At the time of recruitment, candidates must have completed a degree that gives access to doctoral studies at Spanish Universities.

The 2018 INPhINIT Programme offers a 3-year doctoral employment contract and a personal development career plan.

Click here for CALL DETAILS and INSCRIPTION.

HELP DESK:
– e-mail address: Training_program@cnic.es
– telephone: +34 91 453 1200 (extension 3106)

Call opening November 7, 2017
Call deadline February 1, 2018
Pre-selection of candidates  April 16, 2018
Oral interviews May 16-17, 2018
Final results May 29, 2018
Research centre – fellow agreement Until June 22, 2018
Start date of fellowships September-October 2018

Older posts

© 2018 Sabio lab

Carefully crafted by hand by ¡Cuánta Ciencia!Up ↑